DENVER, Colo., Aug 26, 2025 (247marketnews.com)- Marker Therapeutics (NASDAQ:MRKR) reported encouraging interim results from its ongoing Phase 1 APOLLO study of MT-601, a novel Multi-Antigen Recognizing T cell (MAR-T) therapy for relapsed B cell lymphoma.
Among Non-Hodgkin Lymphoma (NHL) patients evaluated, 66% achieved an objective response, and 50% reached complete response (CR). These patients were heavily pre-treated, with a median of five prior therapies, including CAR-T and bispecific antibody treatments. Responses showed early durability, with several patients maintaining remission for over six months and three beyond one year.
The study, which includes patients who relapsed after or were ineligible for anti-CD19 CAR-T cell therapy, also demonstrated a favorable safety profile. No dose-limiting toxicities (DLTs) or immune-effector cell associated neurotoxicity syndrome (ICANS) were observed in the dose escalation cohort (100×10⁶ to 400×10⁶ cells).
The dose expansion phase will focus on patients with Diffuse Large B Cell Lymphoma (DLBCL) at the maximum pre-specified dose. Marker’s CEO, Dr. Juan Vera, noted that the study data “underscore the potential of MT-601 in heavily pre-treated patients with lymphoma,” particularly those who progress after CAR-T.
With 78% response rate also seen in Hodgkin Lymphoma patients, MT-601 could represent a significant advance in treatment-resistant lymphomas across multiple subtypes.
The post Marker Therapeutics Reports Promising Phase 1 Lymphoma Trial of MT-601 Responses appeared first on 24/7 MarketNews.
